John Cavan
Chief Executive Officer chez HEPION PHARMACEUTICALS, INC.
Fortune : 1 860 $ au 31/03/2024
Profil
John T.
Cavan is currently the Director at Vantage Health System, Inc. and the Chief Executive & Financial Officer at Hepion Pharmaceuticals, Inc. He previously worked as the Chief Accounting Officer & Vice President at Aegerion Pharmaceuticals, Inc., the Chief Accounting Officer at Stemline Therapeutics, Inc., and the Controller at AlgoRx Pharmaceuticals, Inc. Mr. Cavan completed his undergraduate degree at Iona College and holds an MBA from Seton Hall University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 27/04/2023 | 747 ( 0,02% ) | 1 860 $ | 31/03/2024 |
Postes actifs de John Cavan
| Sociétés | Poste | Début |
|---|---|---|
| HEPION PHARMACEUTICALS, INC. | Chief Executive Officer | 04/12/2023 |
| Vantage Health System, Inc. | Director/Board Member | - |
Anciens postes connus de John Cavan
| Sociétés | Poste | Fin |
|---|---|---|
| AEGERION PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 01/02/2012 |
| STEMLINE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/02/2012 |
AlgoRx Pharmaceuticals, Inc.
 AlgoRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AlgoRx Pharmaceuticals, Inc. was a pharmaceutical company. The company developed and commercialized drugs for pain management. The company was founded in 2001 and was hedquartered in Secaucus, NJ. | Comptroller/Controller/Auditor | - |
Formation de John Cavan
| Iona College | Undergraduate Degree |
| Seton Hall University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HEPION PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
AlgoRx Pharmaceuticals, Inc.
AlgoRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AlgoRx Pharmaceuticals, Inc. was a pharmaceutical company. The company developed and commercialized drugs for pain management. The company was founded in 2001 and was hedquartered in Secaucus, NJ. | Health Technology |
| Vantage Health System, Inc. |
